207 related articles for article (PubMed ID: 34515105)
1. Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.
Yanai S; Toya Y; Sugai T; Matsumoto T
Digestion; 2021; 102(6):965-973. PubMed ID: 34515105
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
4. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
[TBL] [Abstract][Full Text] [Related]
5. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
Dougan M
Immunol Rev; 2023 Sep; 318(1):11-21. PubMed ID: 37455375
[TBL] [Abstract][Full Text] [Related]
7. Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis.
Pisuchpen N; Durbin SM; Mooradian MJ; Fintelmann FJ; Reynolds KL; Dougan M; Kambadakone A
Eur Radiol; 2021 Dec; 31(12):8868-8878. PubMed ID: 34081152
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
9. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
10. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
[TBL] [Abstract][Full Text] [Related]
11. P067 Immune Checkpoint Inhibitor Colitis in a Community-Based Hospital System.
Rampersad A; Abrams G; Bauer C
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17-S18. PubMed ID: 37461984
[TBL] [Abstract][Full Text] [Related]
12. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.
de Andrea CE; Perez-Gracia JL; Castanon E; Ponz-Sarvise M; Echeveste JI; Melero I; Sanmamed MF; Rodriguez-Ruiz ME
Oncoimmunology; 2020 May; 9(1):1760676. PubMed ID: 32934876
[TBL] [Abstract][Full Text] [Related]
13. Mesalamine and cholestyramine for immune checkpoint inhibitor-mediated diarrhea and colitis.
Hollander B; Khurana S; Jacob JS; Altan M; Wang J; Zhao D; Varatharajalu K; Alasadi M; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3637-3648. PubMed ID: 35972690
[TBL] [Abstract][Full Text] [Related]
14. Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity.
Shatila M; Ma W; Cui Y; Naz S; S Thomas A; N De Toni E; Török HP; Khaled NB; Altan M; Schneider B; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7793-7803. PubMed ID: 37029815
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitors-Induced Colitis.
Tian Y; Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2018; 995():151-157. PubMed ID: 30539510
[TBL] [Abstract][Full Text] [Related]
16. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
[TBL] [Abstract][Full Text] [Related]
18. Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis.
Inoue S; Kono M; Fukuda H; Shimamoto Y; Nakagawa K; Ohmori M; Iwagami H; Matsuno K; Iwatsubo T; Nakahira H; Matsuura N; Shichijo S; Maekawa A; Kanesaka T; Yamamoto S; Takeuchi Y; Higashino K; Uedo N; Kitamura M; Nakatsuka S; Kunimasa K; Kumagai T; Isei T; Ishihara R
J Gastroenterol Hepatol; 2021 May; 36(5):1180-1186. PubMed ID: 32888202
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal Tract Adverse Events.
Abu-Sbeih H; Wang Y
Adv Exp Med Biol; 2020; 1244():247-253. PubMed ID: 32301019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
